Telix Pharmaceuticals Limited American Depositary Shares (TLX)

• Market cap: $3.17B
• 1 day: 2.93%
• 5 days: 3.04%
• 1 month: -17.85%
• 3 months: -43.37%
• 6 months: -46.14%
• Year to date: -36.8%
• 1 year: -37.43%
• 5 years: -37.43%
• 10 years: -37.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Employees: 554

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,500% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 1

812% more capital invested

Capital invested by funds: $799K [Q1] → $7.29M (+$6.49M) [Q2]

250% more funds holding

Funds holding: 6 [Q1] → 21 (+15) [Q2]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.12% more ownership

Funds ownership: 0.01% [Q1] → 0.13% (+0.12%) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20
• Avg. target: $21
• High target: $22

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns	$20	Buy Maintained	10 Sep 2025
Wedbush David Nierengarten	$22	Outperform Reiterated	28 Aug 2025